Not all patients will want to take triplet therapy, but those with high-volume prostate cancer who are chemotherapy eligible are usually a good fit, explained Neal D. Shore, MD, FACS.
For patients with metastatic hormone-sensitive prostate cancer, recent research has shown that triplet therapy has a benefit over doublet therapy.
Both the PEACE-1 and ARASENS trials have combined classic testosterone suppression, androgen-deprivation therapy, with an androgen receptor pathway inhibitor and have shown a benefit in progression-free and overall survival in these patients, explained Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center. In PEACE-1, patients received abiraterone acetate with prednisone plus docetaxel, and in ARASENS, patients received darolutamide with docetaxel.1,2
The addition of docetaxel means a multidisciplinary team is important, he added. Many urologists won’t give docetaxel and will send the patient to a medical oncologist. He discussed the benefits of triplet therapy at the American Urological Association annual meeting.
At the Advanced Prostate Cancer Consensus Conference, there were discussions around who benefits from triplet therapies, Shore said. From his own perspective, the patients who are a good fit will be fit for chemotherapy, with good metabolic parameters and no neuropathy issues. But more importantly, patients have to want to take proactive measures.
“There may be some patients who just don't want to deal with the added adverse reaction profile, and I respect that,” he said. But certain patients with visceral metastases, a significant amount of bone disease, who may have symptomatic discomfort, and who have liver metastases are high on Shore’s list to prioritize for triplet therapy.
References
1. Fizazi K, Foulon S, Carles J, et al; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1
2. Smith MR, Hussain M, Saad F, et al; ARASENS trial investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132-1142. doi:10.1056/NEJMoa2119115
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More